Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR

Key Points

• Braidwell LP increased its Kymera Therapeutics stake by 12% in the second quarter, acquiring 40,604 shares and bringing its total holdings to 378,163 shares valued at approximately $43.4 million.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $128.70; Guggenheim recently raised its target to $170.
• Kymera beat quarterly expectations, reporting an adjusted loss of $0.62 per share versus the anticipated $0.71 loss and revenue of $65 million, although insiders sold $386.2 million worth of shares over the past three months.

Braidwell LP boosted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 12.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 378,163 shares of the company's stock after buying an additional 40,604 shares during the quarter. Kymera Therapeutics makes up 1.6% of Braidwell LP's investment portfolio, making the stock its 19th largest holding. Braidwell LP owned 0.45% of Kymera Therapeutics worth $43,364,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the stock. GAMMA Investing LLC grew its stake in shares of Kymera Therapeutics by 27.5% in the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company's stock worth $52,000 after acquiring an additional 98 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Kymera Therapeutics during the fourth quarter worth about $63,000. Finally, Osaic Holdings Inc. grew its position in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have commented on KYMR shares. Guggenheim lifted their target price on shares of Kymera Therapeutics from $135.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday. Canaccord Genuity Group upped their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the company a "buy" rating in a report on Friday, June 26th. Deutsche Bank Aktiengesellschaft initiated coverage on Kymera Therapeutics in a research report on Thursday, July 30th. They set a "hold" rating and a $120.00 price target for the company. Brookline Capital Markets reiterated a "buy" rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, BTIG Research reissued a "buy" rating and issued a $134.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $128.70.

Insider Transactions at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 77,109 shares of the company's stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the transaction, the chief financial officer owned 244,883 shares of the company's stock, valued at $28,151,749.68. This represents a 23.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Nello Mainolfi sold 80,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total value of $9,223,200.00. Following the transaction, the chief executive officer owned 666,568 shares of the company's stock, valued at $76,848,624.72. The trade was a 10.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,587,629 shares of company stock valued at $386,183,782 in the last three months. 15.98% of the stock is currently owned by company insiders.

Kymera Therapeutics Stock Down 0.4%

KYMR opened at $118.63 on Thursday. Kymera Therapeutics, Inc. has a twelve month low of $40.10 and a twelve month high of $130.05. The company's 50-day moving average price is $113.96 and its two-hundred day moving average price is $94.49. The stock has a market cap of $9.86 billion, a price-to-earnings ratio of -36.61 and a beta of 1.96.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same quarter last year, the business posted ($0.95) EPS. Kymera Therapeutics's quarterly revenue was up 465.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source